iifl-logo

Glenmark Pharmaceuticals Ltd Historical Data

Add as a Preferred Source on Google
₹2,648
(1.51%)
Nov 20, 2026|03:57:38 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Glenmark Pharmaceuticals Ltd Historical Data

21/10/2026calendar-icon
21/11/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

21-Oct-2026

2,216

2,249.82,163.12,194.137,5121,24,81,02,797.32,80,124

22-Oct-2026

2,168

2,218.82,160.32,198.536,9631,26,61,95,590.53,18,809

23-Oct-2026

2,196

2,203.82,101.62,166.651,6441,90,58,67,328.54,67,214

26-Oct-2026

2,135.6

2,2292,1332,225.846,9342,12,92,47,9434,99,063

27-Oct-2026

2,214.7

2,2752,214.62,265.734,5371,08,86,57,713.32,04,508

28-Oct-2026

2,268

2,3182,261.92,30025,9971,04,78,22,1531,83,204

29-Oct-2026

2,311

2,3392,295.32,33923,99253,74,94,111.589,902

30-Oct-2026

2,336

2,337.32,291.32,298.732,42299,24,15,8962,20,787

02-Nov-2026

2,306

2,400.12,3062,38278,3993,68,77,19,608.47,36,407

03-Nov-2026

2,393.8

2,4202,360.12,40860,0822,21,80,97,008.74,75,805

04-Nov-2026

2,405

2,516.82,380.12,504.734,0011,76,50,29,296.93,14,182

05-Nov-2026

2,538

2,542.22,456.92,481.850,6602,25,47,96,988.83,70,408

06-Nov-2026

2,365.5

2,682.52,365.52,5901,95,57012,94,65,32,243.110,63,843

08-Nov-2026

2,600

2,618.12,572.52,594.99,46829,08,74,192.535,626

09-Nov-2026

2,590

2,7142,572.22,671.11,06,7744,79,09,50,181.97,90,300

11-Nov-2026

2,670

2,689.22,635.72,677.245,1621,77,34,39,168.83,14,338

12-Nov-2026

2,665

2,6802,6342,659.871,5582,40,41,73,882.64,87,902

13-Nov-2026

2,657.8

2,679.92,628.62,64042,1971,16,74,50,727.31,94,621

16-Nov-2026

2,643

2,686.32,6202,632.928,40993,15,99,222.91,31,118

17-Nov-2026

2,632.9

2,6482,600.22,615.821,16276,71,14,039.71,57,673

18-Nov-2026

2,663.6

2,691.52,625.12,646.162,7762,89,46,27,810.13,11,386

19-Nov-2026

2,655.8

2,666.72,608.52,608.530,0171,03,43,26,332.21,92,198

Glenmark Pharma.: Related NEWS

Glenmark Pharma Q3 FY26 Profit Rises 16% to ₹403.2 Crore

Revenue from North America increased 24% year on year to ₹970.6 crore, including income from the out licensing of ISB 2001.

31 Jan 2026|02:22 PM
Read More
Top Stocks for Today - 25th September 2025

Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.

25 Sep 2025|06:57 AM
Read More
Top Stocks for Today - 23rd September 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.

23 Sep 2025|07:01 AM
Read More
Glenmark subsidiary gets $700 Million in licensing deal; stock gains

At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.

9 Sep 2025|02:31 PM
Read More
Glenmark Pharma Q1 Net Profit Falls 86% YoY to ₹47 Crore

Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.

18 Aug 2025|01:03 PM
Read More
Top Stocks for Today - 18th August 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.

18 Aug 2025|08:14 AM
Read More
Glenmark Shares Surge 10% After AbbVie Inks Licensing Deal for ISB 2001

The compound is currently in Phase 1B clinical trials, being studied for multiple myeloma, a tough-to-treat form of blood cancer.

11 Jul 2025|09:48 AM
Read More
Top Stocks for Today - 11th July 2025

Here are some of the stocks that may see significant price movement today: Tata Consultancy Services, IREDA, Glenmark Pharma, etc.

11 Jul 2025|07:20 AM
Read More
Top Stocks for Today - 26th May 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.

26 May 2025|06:34 AM
Read More
Glenmark Pharma’s cancer drug receive FDA ‘fast track’ status

ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.

6 May 2025|09:31 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.